Context Therapeutics Inc.
10/20/2025 | Press release | Distributed by Public on 10/20/2025 16:49
Material Event (Form 8-K)
Item 8.01 Other Events.
As previously disclosed by Context Therapeutics Inc. (the "Company") on that certain Current Report on Form 8-K filed on February 28, 2025 with the U.S. Securities and Exchange Commission (the "SEC"), on February 27, 2025, the Company received written notice (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule") because the Company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Notification Letter provided the Company an initial 180 calendar day period, or until August 26, 2025, in which to regain compliance, pursuant to Nasdaq Listing Rule 5810(c)(3)(A).
As previously disclosed by the Company on that certain Current Report on Form 8-K filed on September 2, 2025 with the SEC, on August 28, 2025, the Company received further written notice from Nasdaq informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until February 23, 2026, to regain compliance with the Minimum Bid Price Rule.
On October 17, 2025, the Company received a letter from Nasdaq notifying the Company that, for the last 10 consecutive business days, the closing bid price of the Company's common stock has been at $1.00 per share or greater and that the Company has regained compliance with the Minimum Bid Price Rule. Accordingly, Nasdaq considers the matter closed.
Context Therapeutics Inc. published this content on October 20, 2025, and is solely responsible for the information contained herein. Distributed via EDGAR on October 20, 2025 at 22:49 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]